Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Progyny Inc (NASDAQ: PGNY) closed at $26.66 in the last session, up 3.57% from day before closing price of $25.74. In other words, the price has increased by $3.57 from its previous closing price. On the day, 1.29 million shares were traded. PGNY stock price reached its highest trading level at $26.92 during the session, while it also had its lowest trading level at $25.8.
Ratios:
We take a closer look at PGNY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.66 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.88. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 2.96. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $29.
On November 12, 2025, KeyBanc Capital Markets Upgraded its rating to Overweight which previously was Sector Weight but kept the price unchanged to $30.
Leerink Partners Upgraded its Market Perform to Outperform on July 08, 2025, while the target price for the stock was maintained at $28.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 11 ’25 when Livingston Mark S. sold 459 shares for $25.50 per share. The transaction valued at 11,704 led to the insider holds 46,983 shares of the business.
Livingston Mark S. bought 459 shares of PGNY for $11,704 on Dec 11 ’25. On Dec 04 ’25, another insider, Swartz Allison, who serves as the EVP, GC of the company, sold 530 shares for $24.59 each. As a result, the insider received 13,033 and left with 72,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PGNY now has a Market Capitalization of 2298402816 and an Enterprise Value of 1981345664. As of this moment, Progyny’s Price-to-Earnings (P/E) ratio for their current fiscal year is 42.21, and their Forward P/E ratio for the next fiscal year is 27.83. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.81 while its Price-to-Book (P/B) ratio in mrq is 4.10. Its current Enterprise Value per Revenue stands at 1.562 whereas that against EBITDA is 21.944.
Stock Price History:
The Beta on a monthly basis for PGNY is 0.96, which has changed by 0.47254002 over the last 52 weeks, in comparison to a change of 0.16067612 over the same period for the S&P500. Over the past 52 weeks, PGNY has reached a high of $27.76, while it has fallen to a 52-week low of $17.01. The 50-Day Moving Average of the stock is 11.03%, while the 200-Day Moving Average is calculated to be 18.12%.
Shares Statistics:
According to the various share statistics, PGNY traded on average about 1.63M shares per day over the past 3-months and 1266280 shares per day over the past 10 days. A total of 86.15M shares are outstanding, with a floating share count of 72.27M. Insiders hold about 16.17% of the company’s shares, while institutions hold 96.68% stake in the company. Shares short for PGNY as of 1765756800 were 5672029 with a Short Ratio of 3.48, compared to 1763078400 on 6677676. Therefore, it implies a Short% of Shares Outstanding of 5672029 and a Short% of Float of 9.090000400000001.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Progyny Inc (PGNY).The consensus estimate for the next quarter is $0.49, with high estimates of $0.52 and low estimates of $0.46.
Analysts are recommending an EPS of between $1.84 and $1.78 for the fiscal current year, implying an average EPS of $1.81. EPS for the following year is $1.96, with 8.0 analysts recommending between $2.14 and $1.8.
Revenue Estimates
According to 10 analysts,. The current quarter’s revenue is expected to be $306.06M. It ranges from a high estimate of $326.32M to a low estimate of $295.87M. As of. The current estimate, Progyny Inc’s year-ago sales were $298.43MFor the next quarter, 10 analysts are estimating revenue of $343.69M. There is a high estimate of $357.81M for the next quarter, whereas the lowest estimate is $330.2M.
A total of 10 analysts have provided revenue estimates for PGNY’s current fiscal year. The highest revenue estimate was $1.3B, while the lowest revenue estimate was $1.27B, resulting in an average revenue estimate of $1.28B. In the same quarter a year ago, actual revenue was $1.17BBased on 10 analysts’ estimates, the company’s revenue will be $1.4B in the next fiscal year. The high estimate is $1.48B and the low estimate is $1.37B.
